Literature DB >> 25805688

Oral lesions and hematology.

İrfan Yavaşoğlu1.   

Abstract

Entities:  

Year:  2015        PMID: 25805688      PMCID: PMC4439920          DOI: 10.4274/tjh.2014.0381

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

TO THE EDITOR

The letter entitled “A Rare Cause of Recurrent Oral Lesions: Chediak-Higashi Syndrome”, written by Karabel et al. and published in a recent issue of your journal, was quite interesting [1]. Here we would like to emphasize some relevant points. A number of systemic diseases, including hematologic disorders, do have manifestations in the orofacial region. Although non-pathognomonic, these manifestations may often represent the initial sign of the underlying hematopoietic disease. Oral ulcers are often idiopathic (recurrent aphthous stomatitis). However, oral ulcers may be findings of gluten enteropathy, inflammatory bowel disease, or Behçet’s disease. In addition, the cause may be deficiency of vitamin B12/folate/iron in 1 in 4 cases [2]. In particular, such lack of uptake may be the cause in patients who present with mental retardation. Therefore, mean corpuscular volume is important. Chediak-Higashi syndrome usually presents in infancy or early childhood; infections involving the lungs, skin, and mucous membranes are commonly encountered. Dental caries and periodontal disease are also common. The most frequent offending organism is S. aureus. Prophylactic trimethoprim/sulfamethoxazole may be useful. Ascorbic acid (200 mg/day) can also be given [3].
  2 in total

Review 1.  Orofacial manifestation of hematological disorders: hemato-oncologic and immuno-deficiency disorders.

Authors:  Titilope A Adeyemo; Wasiu L Adeyemo; Adewumi Adediran; Abd Jaleel A Akinbami; Alani S Akanmu
Journal:  Indian J Dent Res       Date:  2011 Sep-Oct

2.  A rare cause of recurrent oral lesions: chediak-higashi syndrome.

Authors:  Müsemma Karabel; Selvi Kelekçi; Velat Sen; Duran Karabel; Ciğdem Aliosmanoğlu; Murat Söker
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.